Mumbai, March 17 -- Amifampridine Tablets, 10 mg, are bioequivalent to Firdapse Tablets, 10 mg, from Catalyst Pharmaceuticals, Inc., and are indicated for the treatment of Lambert-Eaton Myasthenic Syndrome in adults and pediatric patients 6 years of age and older. This product will be manufactured at Lupin's Goa facility in India.

Amifampridine Tablets, 10 mg (RLD Firdapse), had an estimated global net sale of $306 million for the fiscal year ended 31 December 2024.

Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (A...